EGFR and small cell lung carcinoma: Future larger prospective clinical trials will also need to validate these findings and give us the chance to look for new resistance signatures, such as the one related to SCLC transformation, which is an important potential mechanism of resistance for to first/second and third-generation EGFR-TKIs (8), but to date, only a new tissue biopsy could allow to find it.